drugset / Trial / NCT05393674
Fedratinib in Combination With Nivolumab
Phase 2
Completed
30 enrolled
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Celgene International II S.á.r.l. · collabProf. F. Heidel, MH Hannover · collab
NaSingle-groupOpen-labelTreatment
Summary
A multicenter, open-label, single arm, phase II study investigating the clinical efficacy of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment
Timeline
- Start
- 2022-06-14
- Primary completion
- 2025-11-05
- Completion
- 2026-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fedratinib | Small molecule | 200 mg | Oral |
| Subject | Fedratinib | Small molecule | 300 mg | Oral |
| Subject | Fedratinib | Small molecule | 400 mg | Oral |
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |